Assay ID | Title | Year | Journal | Article |
AID1658802 | Volume of distribution at steady state in Sprague-Dawley rat at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658808 | Half life in Beagle dog at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658819 | In vivo inhibition of lysoPLD activity of ATX in SCID mouse plasma xenografted with human MDA-MB-231 cells at 100 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three times weekly for 5 weeks and measured at | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658784 | Inhibition of recombinant human ATX assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrs | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658813 | Oral bioavailability in Beagle dog at 1 mg/kg administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658820 | Volume of distribution at steady state in cynomolgus monkey at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658792 | Protein binding in human plasma measured after 4 hrs by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658814 | Oral bioavailability in Sprague-Dawley rat at 1 mg/kg administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658822 | Half life in cynomolgus monkey at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658804 | Half life in Sprague-Dawley rat at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658800 | Half life in SCID mouse at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658812 | Oral bioavailability in cynomolgus monkey at 1 mg/kg administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658805 | Clearance in Sprague-Dawley rat at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658801 | Cmax in Sprague-Dawley rat at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658810 | Clearance in Beagle dog at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658799 | Cmax in SCID mouse at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658803 | Half life in Sprague-Dawley rat at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658809 | Half life in Beagle dog at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658818 | In vivo inhibition of lysoPLD activity of ATX in SCID mouse plasma xenografted with human MDA-MB-231 cells at 30 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three times weekly for 5 weeks and measured at 1 | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658815 | Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg, po administered twice daily for 32 days and measured on day 33 relative to control | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658816 | Potentiation of paclitaxel-induced antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 30 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three ti | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658793 | Protein binding in rat plasma measured after 4 hrs by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658806 | Cmax in Beagle dog at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658823 | Clearance in cynomolgus monkey at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658817 | Potentiation of paclitaxel-induced antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg, po administered twice daily for 32 days in combination with paclitaxel at 20 mg/kg, ip three t | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658811 | Cmax in cynomolgus monkey at 1 mg/kg, po administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658807 | Volume of distribution at steady state in Beagle dog at 0.3 mg/kg, iv administered as single dose by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658798 | AUC in Sprague-Dawley rat at 0.5 mg/kg, po administered as single cassette dosing by LC-MS/MS analysis | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
AID1658791 | Inhibition of LysoPLD activity of ATX in human plasma assessed as reduction in choline release using LPC(16:0) as substrate incubated for 15 hrs | 2020 | ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
| ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |